phrykt

Connect Biopharma Holdings Ltd (CNTB): who owns it and who trades it

As of Nov 16, 2026, CNTB insiders reported 2 purchases worth $4.4M in the last 12 months. The largest buyer was James Huang (Director), with $4.4M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Connect Biopharma Holdings

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CNTB

56 funds and institutions reported CNTB shares worth $33.1M at the end of Q2 2026, about 25% of the company. The largest holder is Ikarian Capital, LLC with 8.0%.

Funds and institutions (13F) 25%Everyone else 75%

10 largest owners, by share of the company

Ikarian Capital, LLC8.0%
683 Capital Management, LLC2.3%
Boothbay Fund Management, LLC1.7%
BlackRock, Inc.1.5%
Perceptive Advisors LLC1.4%
ADAR1 Capital Management, LLC1.2%
BML Capital Management, LLC1.0%
Silverarc Capital Management, LLC1.0%
Richmond Brothers, Inc.0.9%
Knott David M Jr0.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ikarian Capital, LLC4.54M8.03%$10.8M-16%
683 Capital Management, LLC1.28M2.27%$3.1M+43%
Boothbay Fund Management, LLC973,7321.72%$2.3M-21%
BlackRock, Inc.871,6531.54%$2.1MNew
Perceptive Advisors LLC792,6961.40%$1.9MNo change
ADAR1 Capital Management, LLC700,0001.24%$1.7M-6%
BML Capital Management, LLC573,2871.01%$1.4M+40%
Silverarc Capital Management, LLC545,0000.96%$1.3MNew
Richmond Brothers, Inc.535,6120.95%$1.3M+12%
Knott David M Jr444,8620.79%$1.1M+15%
Stonepine Capital Management, LLC364,2540.64%$867K+18%
Marshall Wace, LLP335,6420.59%$799K+408%
Geode Capital Management, LLC257,4540.46%$613K+701%
Two Sigma Investments, LP199,3810.35%$475K+320%
Diadema Partners LP196,9850.35%$469K-2%
Burkehill Global Management, LP150,0000.27%$357KNo change
Vanguard Portfolio Management LLC102,7550.18%$245KNew
Susquehanna International Group, LLP102,1480.18%$243K-63%
Renaissance Technologies LLC87,3000.15%$208K-28%
Northern Trust Corp82,8620.15%$197KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CNTB insiders reported $4.4M of open-market purchases and $0 of sales.

Purchases, 12 months
$4.4M
2 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
May 29, 2026
Filed Jun 2, 2026

Purchases and sales by month

$4M$4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 29, 2026James HuangDirectorPurchase150,000$2.48$372KForm 4
Mar 31, 2026James HuangDirectorPurchase1.16M$3.45$4MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
James HuangDirector$4.4M–May 29, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CNTB short interest

Moderate short interest. 5.9% of CNTB shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went up 231%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.83M CNTB shares were sold short, 5.9% of the shares outstanding, down 0.7% from the report before. At the average daily volume of 913,658 shares, buying them all back would take about 4.2 trading days (days to cover).

Shares short, % of all shares

5.94%May 15Oct 306.76%

Days to cover

4.2May 15Oct 309.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.83M5.94%-1%913,6584.2
Oct 15, 20263.86M6.13%+10%2.23M1.7
Sep 30, 20263.50M5.56%+26%15.99M1.0
Sep 15, 20262.77M4.41%+40%2.82M1.0
Aug 31, 20261.99M3.16%+9%476,8994.2
Aug 14, 20261.82M2.89%-12%407,4294.5
Jul 31, 20262.06M3.27%-0%256,7938.0
Jul 15, 20262.06M3.65%+55%740,9642.8
Jun 30, 20261.33M2.35%+25%627,6412.1
Jun 15, 20261.06M1.88%-9%261,9544.0
May 29, 20261.17M2.06%+1%198,7635.9
May 15, 20261.16M2.05%+2%140,3478.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Connect Biopharma Holdings company events

Connect Biopharma Holdings filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 30, 2026.

  1. Sep 30, 2026AnnouncementThe Company announced topline results for the COPD Study. Filing
  2. Sep 15, 2026AnnouncementThe Company announced topline results for the Asthma Study. Filing
  3. Aug 12, 2026ResultsReleased financial results. Filing
  4. May 12, 2026ResultsReleased financial results. Filing
  5. Apr 23, 2026AnnouncementThe Company issued a press release announcing that the DMC has completed its review of the pre-specified interim analysis of efficacy with no recommendation for change in sample size. Filing
  6. Mar 31, 2026ResultsReleased financial results. Filing
  7. Mar 30, 2026AgreementConnect Biopharma Holdings Limited entered into a securities purchase agreement with the purchasers named therein, for the private placement of 6,130,000 shares of the Company’s ordinary shares, par value $0.000174 per share, at a price of $3.25 per Share with respect to any Purchaser that is not… Filing
  8. Dec 23, 2025LeadershipKan Chen, Ph.D., a partner at Qiming Venture Partners, notified Connect Biopharma Holdings Limited of his decision to resign from the Board of Directors of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Connect Biopharma Holdings financials

Famous investors that hold CNTB

3 of the 50 well-known investors we track reported holding CNTB in their latest 13F filing. The largest position is Israel Englander's, worth $417K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026378,839$417K0.0%+767%
Ken Griffin · Citadel AdvisorsQ3 2026116,021$128K0.0%New
Jim Simons · Renaissance TechnologiesQ3 202663,200$69.5K0.0%-28%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named CNTB in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Ikarian Capital, LLC13G/A3.4%
Nov 16, 2026Ikarian Capital, LLC13G/A3.4%
Nov 3, 2026Qiming Managing Directors Fund V, L.P.13G/A0.1%
Nov 3, 2026Qiming Managing Directors Fund V, L.P.13G/A0.1%
Oct 6, 2026BML Investment Partners, L.P.13G6.1%
Oct 6, 2026BML Investment Partners, L.P.13G6.1%

Questions about Connect Biopharma Holdings Ltd (CNTB) stock

Who owns the most CNTB stock?

The largest reported owner of Connect Biopharma Holdings Ltd (CNTB) is Ikarian Capital, LLC, with 8.0% of the company. In total, 56 funds and institutions reported holding CNTB at the end of Q2 2026, together about 25% of the shares. See the largest owners.

Are CNTB insiders buying or selling?

In the last 12 months, CNTB insiders reported 2 open-market purchases worth $4.4M and no sales. The latest trade was on May 29, 2026. See every trade.

What is the short interest in CNTB?

As of Oct 30, 2026, 3.83M CNTB shares were sold short, 5.9% of the shares outstanding, down 0.7% from the report before. At the average daily volume of 913,658 shares, buying them all back would take about 4.2 trading days (days to cover). See the history.

Which famous investors hold CNTB?

3 of the 50 well-known investors we track reported CNTB in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $417K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.